Sirna Therapeutics, Inc., a biotechnology company, develops therapeutics based on RNA interference (RNAi) technology. It engages in the research, preclinical, and/or clinical development with product candidates in the various areas, including age-related macular degeneration (AMD), chronic hepatitis, dermatology, asthma, Huntington's disease (HD), oncology, and diabetes. The company offers Sirna-027, which completed phase I clinical trial is used for the treatment of AMD; Sirna-034, which is under preclinical stage is used for the treatment of hepatitis C virus; and various drugs under preclinical stage of development for asthma, HD, chronic hepatitis, diabetes, and dermatology. It has strategic alliances with Allergan, Inc., Eli Lilly and Company, Targeted Genetics, Protiva, Archemix Corporation, and GlaxoSmithKline. The company, formerly known as Ribozyme Pharmaceuticals, Inc., was founded in 1992 and changed its name to Sirna Therapeutics, Inc. in 2003. Sirna Therapeutics is headquartered in San Francisco, California. As of December 29, 2006 Sirna Therapeutics, Inc. operates as a subsidiary of Merck & Co., Inc.